Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Kidney Cancer
Kidney Cancer Patients Treated With Sutent Report Experiencing Lower Severity of Symptoms Compared With Interferon-Alfa, Data Show
August 19th, 2008
Pfizer announced that patients with advanced renal cell carcinoma (RCC), also known as advanced kidney cancer, treated with single-agent, oral SUTENT® (sunitinib malate) reported experiencing significantly lower severity of symptoms like bone pain and breathlessness, among others, than patients treated with IFN-a. This secondary analysis was published in the August 1, 2008, issue of the Journal of Clinical Oncology. These data are from a large, randomized, pivotal Phase 3 trial which previously demonstrated that SUTENT more than doubled progression-free survival versus IFN-a. "Symptoms associated with a devastating and debilitating illness like...
Source: Cancer Weekly (2008-08-19)
|
